GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Wuhan Easy Diagnosis Biomedicine Co Ltd (SZSE:002932) » Definitions » Equity-to-Asset

Wuhan Easy Diagnosis Biomedicine Co (SZSE:002932) Equity-to-Asset : 0.84 (As of Mar. 2024)


View and export this data going back to 2018. Start your Free Trial

What is Wuhan Easy Diagnosis Biomedicine Co Equity-to-Asset?

Equity to Asset ratio is calculated as total stockholders equity divided by total asset. Wuhan Easy Diagnosis Biomedicine Co's Total Stockholders Equity for the quarter that ended in Mar. 2024 was ¥6,045.5 Mil. Wuhan Easy Diagnosis Biomedicine Co's Total Assets for the quarter that ended in Mar. 2024 was ¥7,240.8 Mil. Therefore, Wuhan Easy Diagnosis Biomedicine Co's Equity to Asset Ratio for the quarter that ended in Mar. 2024 was 0.84.

The historical rank and industry rank for Wuhan Easy Diagnosis Biomedicine Co's Equity-to-Asset or its related term are showing as below:

SZSE:002932' s Equity-to-Asset Range Over the Past 10 Years
Min: 0.39   Med: 0.82   Max: 0.97
Current: 0.84

During the past 13 years, the highest Equity to Asset Ratio of Wuhan Easy Diagnosis Biomedicine Co was 0.97. The lowest was 0.39. And the median was 0.82.

SZSE:002932's Equity-to-Asset is ranked better than
81.65% of 872 companies
in the Medical Devices & Instruments industry
Industry Median: 0.64 vs SZSE:002932: 0.84

Wuhan Easy Diagnosis Biomedicine Co Equity-to-Asset Historical Data

The historical data trend for Wuhan Easy Diagnosis Biomedicine Co's Equity-to-Asset can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Wuhan Easy Diagnosis Biomedicine Co Equity-to-Asset Chart

Wuhan Easy Diagnosis Biomedicine Co Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Equity-to-Asset
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.96 0.77 0.82 0.71 0.82

Wuhan Easy Diagnosis Biomedicine Co Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Equity-to-Asset Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.74 0.76 0.79 0.82 0.84

Competitive Comparison of Wuhan Easy Diagnosis Biomedicine Co's Equity-to-Asset

For the Medical Devices subindustry, Wuhan Easy Diagnosis Biomedicine Co's Equity-to-Asset, along with its competitors' market caps and Equity-to-Asset data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Wuhan Easy Diagnosis Biomedicine Co's Equity-to-Asset Distribution in the Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, Wuhan Easy Diagnosis Biomedicine Co's Equity-to-Asset distribution charts can be found below:

* The bar in red indicates where Wuhan Easy Diagnosis Biomedicine Co's Equity-to-Asset falls into.



Wuhan Easy Diagnosis Biomedicine Co Equity-to-Asset Calculation

Equity to Asset ratio measures the ratios of the portion of the asset owned by shareholders out of the total asset. It indicates the leverage of the company, and the amount of debt the company uses in its operation.

Equity to Asset ratio is calculated by dividing total stockholders equity by total asset.

Wuhan Easy Diagnosis Biomedicine Co's Equity to Asset Ratio for the fiscal year that ended in Dec. 2023 is calculated as

Equity to Asset (A: Dec. 2023 )=Total Stockholders Equity/Total Assets
=6025.89/7386.6
=0.82

Wuhan Easy Diagnosis Biomedicine Co's Equity to Asset Ratio for the quarter that ended in Mar. 2024 is calculated as

Equity to Asset (Q: Mar. 2024 )=Total Stockholders Equity/Total Assets
=6045.503/7240.838
=0.83

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Wuhan Easy Diagnosis Biomedicine Co  (SZSE:002932) Equity-to-Asset Explanation

Equity to Asset ratio can vary greatly across different industries, as they have different capital structure. A company with smaller Equity to Asset ratio (more leveraged) may have higher ROE % because of the leverage.

For banks, the required minimum Equity to Asset ratio by regulation is 5%. Some stronger banks may have Equity to Asset Ratio of more than 10%.


Wuhan Easy Diagnosis Biomedicine Co Equity-to-Asset Related Terms

Thank you for viewing the detailed overview of Wuhan Easy Diagnosis Biomedicine Co's Equity-to-Asset provided by GuruFocus.com. Please click on the following links to see related term pages.


Wuhan Easy Diagnosis Biomedicine Co (SZSE:002932) Business Description

Traded in Other Exchanges
N/A
Address
No. 1 Dongxin Road, 2 Floor, Building E, International Students Pioneer Park, Guandong Science and Technology Park, Donghu Development Zone, Hubei, Wuhan, CHN, 430075
Wuhan Easy Diagnosis Biomedicine Co Ltd is engaged in the research and development, production and sales of in vitro diagnostic reagents and supporting instruments and mobile ECG products. The company's product profile consists of Molecular diagnosis, Chemiluminescence, Blood gas analysis, and others. It also provides various other solutions such as Mingde Biomolecular Diagnostic Service Solution, Mingde Biothoracic Center Solution, POCT Solution, Remote ECG network construction solution, and others.
Executives
Wang Rui Directors, executives
Wang Jian Fei Director

Wuhan Easy Diagnosis Biomedicine Co (SZSE:002932) Headlines

No Headlines